Literature DB >> 32457108

Novel Antiparasitic Activity of the Antifungal Lead Occidiofungin.

Jingbo Ma1,2, Fengguang Guo1, Zi Jin1, Mengxin Geng3, Min Ju3, Akshaya Ravichandran4, Ravi Orugunty4, Leif Smith5, Guan Zhu6, Haili Zhang6.   

Abstract

Novel antiparasitic activity was observed for the antifungal occidiofungin. It efficaciously and irreversibly inhibited the zoonotic enteric parasite Cryptosporidium parvum in vitro with limited cytotoxicity (50% effective concentration [EC50] = 120 nM versus 50% cytotoxic concentration [TC50] = 988 nM), and its application disrupted the parasite morphology. This study expands the spectrum of activity of a glycolipopeptide named occidiofungin. Occidiofungin has poor gastrointestinal tract absorption properties, supporting future investigations into its potential activities on other enteric parasites.
Copyright © 2020 American Society for Microbiology.

Entities:  

Keywords:  Cryptosporidium parvum; cytotoxicity; efficacy; in vitro; occidiofungin; protozoan parasite

Mesh：

Substances：

Year:  2020        PMID： 32457108      PMCID： PMC7526809          DOI： 10.1128/AAC.00244-20

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  19 in total

1.  Development of 5-Aminopyrazole-4-carboxamide-based Bumped-Kinase Inhibitors for Cryptosporidiosis Therapy.

Authors:  Wenlin Huang; Matthew A Hulverson; Ryan Choi; Samuel L M Arnold; Zhongsheng Zhang; Molly C McCloskey; Grant R Whitman; Robert C Hackman; Kasey L Rivas; Lynn K Barrett; Kayode K Ojo; Wesley C Van Voorhis; Erkang Fan
Journal:  J Med Chem       Date:  2019-03-15       Impact factor: 7.446

2.  Occidiofungin's chemical stability and in vitro potency against Candida species.

Authors:  Dayna Ellis; Jiten Gosai; Charles Emrick; Rachel Heintz; Lanette Romans; Donna Gordon; Shi-En Lu; Frank Austin; Leif Smith
Journal:  Antimicrob Agents Chemother       Date:  2011-11-21       Impact factor: 5.191

3.  Nonclinical toxicological evaluation of occidiofungin, a unique glycolipopeptide antifungal.

Authors:  Wei Tan; Jim Cooley; Frank Austin; Shi-En Lu; Stephen B Pruett; Leif Smith
Journal:  Int J Toxicol       Date:  2012-06-11       Impact factor: 2.032

4.  Occidiofungin, a unique antifungal glycopeptide produced by a strain of Burkholderia contaminans.

Authors:  Shi-En Lu; Jan Novak; Frank W Austin; Ganyu Gu; Dayna Ellis; Marion Kirk; Shawanda Wilson-Stanford; Marco Tonelli; Leif Smith
Journal:  Biochemistry       Date:  2009-09-08       Impact factor: 3.162

5.  Amelioration of Cryptosporidium parvum infection in vitro and in vivo by targeting parasite fatty acyl-coenzyme A synthetases.

Authors:  Fengguang Guo; Haili Zhang; Jason M Fritzler; S Dean Rider; Lixin Xiang; Nina N McNair; Jan R Mead; Guan Zhu
Journal:  J Infect Dis       Date:  2013-11-23       Impact factor: 5.226

6.  Necessity of Bumped Kinase Inhibitor Gastrointestinal Exposure in Treating Cryptosporidium Infection.

Authors:  Samuel L M Arnold; Ryan Choi; Matthew A Hulverson; Deborah A Schaefer; Sumiti Vinayak; Rama S R Vidadala; Molly C McCloskey; Grant R Whitman; Wenlin Huang; Lynn K Barrett; Kayode K Ojo; Erkang Fan; Dustin J Maly; Michael W Riggs; Boris Striepen; Wesley C Van Voorhis
Journal:  J Infect Dis       Date:  2017-07-01       Impact factor: 5.226

7.  Lysyl-tRNA synthetase as a drug target in malaria and cryptosporidiosis.

Authors:  Beatriz Baragaña; Barbara Forte; Ryan Choi; Stephen Nakazawa Hewitt; Juan A Bueren-Calabuig; João Pedro Pisco; Caroline Peet; David M Dranow; David A Robinson; Chimed Jansen; Neil R Norcross; Sumiti Vinayak; Mark Anderson; Carrie F Brooks; Caitlin A Cooper; Sebastian Damerow; Michael Delves; Karen Dowers; James Duffy; Thomas E Edwards; Irene Hallyburton; Benjamin G Horst; Matthew A Hulverson; Liam Ferguson; María Belén Jiménez-Díaz; Rajiv S Jumani; Donald D Lorimer; Melissa S Love; Steven Maher; Holly Matthews; Case W McNamara; Peter Miller; Sandra O'Neill; Kayode K Ojo; Maria Osuna-Cabello; Erika Pinto; John Post; Jennifer Riley; Matthias Rottmann; Laura M Sanz; Paul Scullion; Arvind Sharma; Sharon M Shepherd; Yoko Shishikura; Frederick R C Simeons; Erin E Stebbins; Laste Stojanovski; Ursula Straschil; Fabio K Tamaki; Jevgenia Tamjar; Leah S Torrie; Amélie Vantaux; Benoît Witkowski; Sergio Wittlin; Manickam Yogavel; Fabio Zuccotto; Iñigo Angulo-Barturen; Robert Sinden; Jake Baum; Francisco-Javier Gamo; Pascal Mäser; Dennis E Kyle; Elizabeth A Winzeler; Peter J Myler; Paul G Wyatt; David Floyd; David Matthews; Amit Sharma; Boris Striepen; Christopher D Huston; David W Gray; Alan H Fairlamb; Andrei V Pisliakov; Chris Walpole; Kevin D Read; Wesley C Van Voorhis; Ian H Gilbert
Journal:  Proc Natl Acad Sci U S A       Date:  2019-03-20       Impact factor: 11.205

8.  A Novel Actin Binding Drug with In Vivo Efficacy.

Authors:  Akshaya Ravichandran; Mengxin Geng; Kenneth G Hull; Jing Li; Daniel Romo; Shi-En Lu; Aaron Albee; Christopher Nutter; Donna M Gordon; Mahmoud A Ghannoum; Steve W Lockless; Leif Smith
Journal:  Antimicrob Agents Chemother       Date:  2018-12-21       Impact factor: 5.191

9.  Quantitative RT-PCR assay for high-throughput screening (HTS) of drugs against the growth of Cryptosporidium parvum in vitro.

Authors:  Haili Zhang; Guan Zhu
Journal:  Front Microbiol       Date:  2015-09-22       Impact factor: 5.640

10.  A Cryptosporidium PI(4)K inhibitor is a drug candidate for cryptosporidiosis.

Authors:  Ujjini H Manjunatha; Sumiti Vinayak; Jennifer A Zambriski; Alexander T Chao; Tracy Sy; Christian G Noble; Ghislain M C Bonamy; Ravinder R Kondreddi; Bin Zou; Peter Gedeck; Carrie F Brooks; Gillian T Herbert; Adam Sateriale; Jayesh Tandel; Susan Noh; Suresh B Lakshminarayana; Siau H Lim; Laura B Goodman; Christophe Bodenreider; Gu Feng; Lijun Zhang; Francesca Blasco; Juergen Wagner; F Joel Leong; Boris Striepen; Thierry T Diagana
Journal:  Nature       Date:  2017-05-31       Impact factor: 49.962
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.